NCCN working group report

Designing clinical trials in the era of multiple biomarkers and targeted therapies

Alan P. Venook, Maria E. Arcila, Al B. Benson, Donald A. Berry, David Ross Camidge, Robert W. Carlson, Toni K. Choueiri, Valerie Guild, Gregory P. Kalemkerian, Razelle Kurzrock, Christine M. Lovly, Amy E. McKee, Robert J. Morgan, Anthony J. Olszanski, Mary W. Redman, Vered Stearns, Joan McClure, Marian L. Birkeland

Research output: Contribution to journalArticle

Abstract

Defining treatment-susceptible or -resistant populations of patients with cancer through the use of genetically defined biomarkers has revolutionized cancer care in recent years for some disease/patient groups. Research continues to show that histologically defined diseases are diverse in their expression of unique mutations or other genetic alterations, however, which presents opportunities for the development of personalized cancer treatments, but increased difficulty in testing these therapies, because potential patient populations are divided into ever smaller numbers. To address some of the growing challenges in biomarker development and clinical trial design, NCCN assembled a group of experts across specialties and solid tumor disease types to begin to define the problems and to consider alternate ways of designing clinical trials in the era of multiple biomarkers and targeted therapies. Results from that discussion are presented, focusing on issues of clinical trial design from the perspective of statisticians, clinical researchers, regulators, pathologists, and information developers.

Original languageEnglish (US)
Pages (from-to)1629-1649
Number of pages21
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume12
Issue number11
StatePublished - Nov 1 2014
Externally publishedYes

Fingerprint

Biomarkers
Clinical Trials
Neoplasms
Therapeutics
Population
Research Personnel
Mutation
Research

ASJC Scopus subject areas

  • Oncology

Cite this

Venook, A. P., Arcila, M. E., Benson, A. B., Berry, D. A., Camidge, D. R., Carlson, R. W., ... Birkeland, M. L. (2014). NCCN working group report: Designing clinical trials in the era of multiple biomarkers and targeted therapies. JNCCN Journal of the National Comprehensive Cancer Network, 12(11), 1629-1649.

NCCN working group report : Designing clinical trials in the era of multiple biomarkers and targeted therapies. / Venook, Alan P.; Arcila, Maria E.; Benson, Al B.; Berry, Donald A.; Camidge, David Ross; Carlson, Robert W.; Choueiri, Toni K.; Guild, Valerie; Kalemkerian, Gregory P.; Kurzrock, Razelle; Lovly, Christine M.; McKee, Amy E.; Morgan, Robert J.; Olszanski, Anthony J.; Redman, Mary W.; Stearns, Vered; McClure, Joan; Birkeland, Marian L.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 12, No. 11, 01.11.2014, p. 1629-1649.

Research output: Contribution to journalArticle

Venook, AP, Arcila, ME, Benson, AB, Berry, DA, Camidge, DR, Carlson, RW, Choueiri, TK, Guild, V, Kalemkerian, GP, Kurzrock, R, Lovly, CM, McKee, AE, Morgan, RJ, Olszanski, AJ, Redman, MW, Stearns, V, McClure, J & Birkeland, ML 2014, 'NCCN working group report: Designing clinical trials in the era of multiple biomarkers and targeted therapies', JNCCN Journal of the National Comprehensive Cancer Network, vol. 12, no. 11, pp. 1629-1649.
Venook, Alan P. ; Arcila, Maria E. ; Benson, Al B. ; Berry, Donald A. ; Camidge, David Ross ; Carlson, Robert W. ; Choueiri, Toni K. ; Guild, Valerie ; Kalemkerian, Gregory P. ; Kurzrock, Razelle ; Lovly, Christine M. ; McKee, Amy E. ; Morgan, Robert J. ; Olszanski, Anthony J. ; Redman, Mary W. ; Stearns, Vered ; McClure, Joan ; Birkeland, Marian L. / NCCN working group report : Designing clinical trials in the era of multiple biomarkers and targeted therapies. In: JNCCN Journal of the National Comprehensive Cancer Network. 2014 ; Vol. 12, No. 11. pp. 1629-1649.
@article{2d20de92de9445e9a7441a2a45a11e2d,
title = "NCCN working group report: Designing clinical trials in the era of multiple biomarkers and targeted therapies",
abstract = "Defining treatment-susceptible or -resistant populations of patients with cancer through the use of genetically defined biomarkers has revolutionized cancer care in recent years for some disease/patient groups. Research continues to show that histologically defined diseases are diverse in their expression of unique mutations or other genetic alterations, however, which presents opportunities for the development of personalized cancer treatments, but increased difficulty in testing these therapies, because potential patient populations are divided into ever smaller numbers. To address some of the growing challenges in biomarker development and clinical trial design, NCCN assembled a group of experts across specialties and solid tumor disease types to begin to define the problems and to consider alternate ways of designing clinical trials in the era of multiple biomarkers and targeted therapies. Results from that discussion are presented, focusing on issues of clinical trial design from the perspective of statisticians, clinical researchers, regulators, pathologists, and information developers.",
author = "Venook, {Alan P.} and Arcila, {Maria E.} and Benson, {Al B.} and Berry, {Donald A.} and Camidge, {David Ross} and Carlson, {Robert W.} and Choueiri, {Toni K.} and Valerie Guild and Kalemkerian, {Gregory P.} and Razelle Kurzrock and Lovly, {Christine M.} and McKee, {Amy E.} and Morgan, {Robert J.} and Olszanski, {Anthony J.} and Redman, {Mary W.} and Vered Stearns and Joan McClure and Birkeland, {Marian L.}",
year = "2014",
month = "11",
day = "1",
language = "English (US)",
volume = "12",
pages = "1629--1649",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "11",

}

TY - JOUR

T1 - NCCN working group report

T2 - Designing clinical trials in the era of multiple biomarkers and targeted therapies

AU - Venook, Alan P.

AU - Arcila, Maria E.

AU - Benson, Al B.

AU - Berry, Donald A.

AU - Camidge, David Ross

AU - Carlson, Robert W.

AU - Choueiri, Toni K.

AU - Guild, Valerie

AU - Kalemkerian, Gregory P.

AU - Kurzrock, Razelle

AU - Lovly, Christine M.

AU - McKee, Amy E.

AU - Morgan, Robert J.

AU - Olszanski, Anthony J.

AU - Redman, Mary W.

AU - Stearns, Vered

AU - McClure, Joan

AU - Birkeland, Marian L.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Defining treatment-susceptible or -resistant populations of patients with cancer through the use of genetically defined biomarkers has revolutionized cancer care in recent years for some disease/patient groups. Research continues to show that histologically defined diseases are diverse in their expression of unique mutations or other genetic alterations, however, which presents opportunities for the development of personalized cancer treatments, but increased difficulty in testing these therapies, because potential patient populations are divided into ever smaller numbers. To address some of the growing challenges in biomarker development and clinical trial design, NCCN assembled a group of experts across specialties and solid tumor disease types to begin to define the problems and to consider alternate ways of designing clinical trials in the era of multiple biomarkers and targeted therapies. Results from that discussion are presented, focusing on issues of clinical trial design from the perspective of statisticians, clinical researchers, regulators, pathologists, and information developers.

AB - Defining treatment-susceptible or -resistant populations of patients with cancer through the use of genetically defined biomarkers has revolutionized cancer care in recent years for some disease/patient groups. Research continues to show that histologically defined diseases are diverse in their expression of unique mutations or other genetic alterations, however, which presents opportunities for the development of personalized cancer treatments, but increased difficulty in testing these therapies, because potential patient populations are divided into ever smaller numbers. To address some of the growing challenges in biomarker development and clinical trial design, NCCN assembled a group of experts across specialties and solid tumor disease types to begin to define the problems and to consider alternate ways of designing clinical trials in the era of multiple biomarkers and targeted therapies. Results from that discussion are presented, focusing on issues of clinical trial design from the perspective of statisticians, clinical researchers, regulators, pathologists, and information developers.

UR - http://www.scopus.com/inward/record.url?scp=84908530231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908530231&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 1629

EP - 1649

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 11

ER -